Months af­ter Imfinzi com­bo flops, As­traZeneca wins NICE en­dorse­ment as lung can­cer monother­a­py

As­traZeneca’s big bet on a com­bi­na­tion of its check­point in­hibitor Imfinzi and in-house CT­LA-4 drug has proved ex­ceed­ing­ly cost­ly, but the British drug­mak­er has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.